74results about How to "Reduce pathological damage" patented technology

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei JNL0025 strain and application thereof. Compared with a commercial strain lactobacillus casei substitute strain, the lactobacillus paracasei JNL0025 provided by the invention has the advantages that the guanine nucleoside conversion rate is improved, the inhibition rate of supernate on XOD is equivalent, and the inhibition on PNP activity can be realized; according to the lactobacillus paracasei JNL0025 disclosed by the invention, the lactobacillus paracasei JNL0025 has the effects of reducing the tendency of pro-inflammatory M1 type macrophages, increasing the proportion of anti-inflammatory M2 type macrophages and inhibiting secretion of pro-inflammatory cytokines TNF-alpha and IL-6, and the lactobacillus paracasei JNL0025 has a better inflammation inhibition effect than the lactobacillus rhamnosus LGG; animal experiment results show that the lactobacillus paracasei JNL0025 provided by the invention can significantly reduce the blood uric acid level of a hyperuricemia model mouse, alleviate the kidney inflammation level and alleviate DSS-induced colitis, and shows a huge application value.

The invention discloses plant lactobacillus WH021 and application thereof in preventing and / or relieving neuroinflammation, and belongs to the technical field of microorganisms. The plant lactobacillus WH021 is separated and purified from excrement of healthy babies, is a probiotic with the function of relieving neuroinflammation, and has good application potential in development of food, health care products and drugs for preventing brain inflammation related diseases caused by chronic inflammation of bodies of middle-aged and elderly people.

The invention discloses an application of isoliensinine in preparation of a medicine for treating staphylococcus aureus infectious arthritis. According to a treatment model of SD rat staphylococcus aureus infectious arthritis, the isoliensinine is proved to be capable of improving excessive inflammatory response of joint tissues infected by staphylococcus aureus and remarkably relieving pathological injury of rat joints, and the isoliensinine has a relatively good treatment effect on staphylococcus aureus infectious arthritis. In addition, the invention reveals that the isoliensinine is combined with a staphylococcus aureus reaction regulatory factor SaeR in a targeted manner, so that the toxicity of staphylococcus aureus is reduced to play a role. Compared with the traditional antibiotic for treating staphylococcus aureus, the isoliensinine has the advantages of no survival pressure on germs and no generation of drug resistance of the germs. Therefore, the isoliensinine has a relatively good potential application prospect in research and development of safe and effective medicines for treating the staphylococcus aureus infectious arthritis.

The invention discloses application of livistona chinensis seed polysaccharide in preparation of a product for relieving or treating liver injury, and belongs to the field of biological medicine, and the liver injury is LPS / D-GalN induced acute liver injury. According to the application disclosed by the invention, by reducing the contents of AST and ALT in liver cells, improving the levels of SOD, CAT and GSH oxidase in the cells, reducing the level of MDA in the cells and reducing the amount of inflammatory factors IL-6, TNF-alpha and NO, the protective effect of the livistona chinensis seed polysaccharide on LPS / D-GalN induced acute liver injury is exerted. The livistona chinensis seed polysaccharide is injected into the intraperitoneal cavity in advance to prevent and treat the acute liver injury induced by LPS / D-GalN. The invention proves the prevention or treatment effect of the livistona chinensis seed polysaccharide in drug-induced acute liver injury, and provides a certain theoretical basis for the development and application of livistona chinensis seeds and the research and development of liver protection products.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The application discloses application of ginsenoside Rb1 in preparation of biological products for improving liver aging and abnormal lipid metabolism. The application research finds that ginsenoside Rb1 (20 mg / kg) can significantly improve the aging phenotype and lipid metabolism disorder of the aging liver through multi-target synergistic effect, and the mechanism is related to inhibition of lipid synthesis, improvement of lipid transport and promotion of lipid oxidation. The application provides a new drug candidate and action mechanism for intervention of aging-related liver diseases such as MASLD / MASH, and has an important clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to a thiophenol compound as well as a preparation method and application thereof. The prepared thiophenol compound is applied to human kidney cells HK-2 and living mice, it is found that the compound can remarkably inhibit peroxidation of cell membrane lipid molecules induced by hypoxia-reoxygenation and further induce cell ferroptosis, and the thiophenol compound has a long-term stable inhibition effect. By pretreating the compound, the levels of creatinine and urea nitrogen in serum after kidney injury can be remarkably reduced, which indicates that the compound can relieve acute kidney injury. Besides, the compound prepared by the invention is used for pretreatment, so that kidney external marrow region injury caused by ischemia-reperfusion is remarkably relieved, lesions such as renal tubular epithelial cell necrosis and the like are effectively relieved, and a new treatment strategy is provided for ferroptosis inhibitors when the compound is applied to kidney ischemia-reperfusion injury repair.

The invention relates to the technical field of medicines, discloses an application of 18 beta-glycyrrhetinic acid in a TMAO inhibitor, and further discloses an application of 18 beta-glycyrrhetinic acid in preparation of medicines for treating chronic diseases such as chronic kidney disease (CKD) and the like. The invention provides 18 beta-glycyrrhetinic acid (18 beta-GA) which is a substance capable of effectively inhibiting choline in intestinal tracts from being metabolized into TMAO for the first time, and the 18 beta-GA is efficiently combined with CutC / D and FMO to inhibit the generation of TMAO, so that the aggravating effect of TMAO on chronic kidney diseases is relieved; the invention further provides a method for improving kidney diseases through a CXCL12 / CXCR4 signal axis after the TMAO is reduced by the 18 beta-glycyrrhetinic acid, a new thought and a new method are provided for developing medicines for treating the TMAO related diseases, and a new way is expected to be developed for treating the chronic kidney diseases.

The invention relates to a traditional Chinese medicine composition for treating chronic kidney diseases and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: astragalus membranaceus, rheum officinale, cassia twig, poria cocos, radix paeoniae rubra, peach kernels and moutan bark. The traditional Chinese medicine components in the traditional Chinese medicine composition are scientific in compatibility, and the traditional Chinese medicine composition has a very remarkable effect on treating the chronic kidney diseases. Researches show that the traditional Chinese medicine composition can effectively treat the chronic kidney disease, improve the kidney function of a kidney disease patient, reduce the serum creatinine level and the urea nitrogen level, increase the expression level of peroxisome related functional enzymes and relieve kidney pathological injuries.

The present invention provides an inhalable bionic nanomaterial for treating bacterial pneumonia of the lungs, and a preparation method and application thereof, belonging to the technical field of drug preparation. Mesoporous polydopamine nanoparticles A are prepared by a one-pot synthesis method using block polyether and 3,3',5,5'-tetramethylbenzidine as templates; levofloxacin is added to A, stirred and centrifuged, and freeze-dried to obtain nanoparticles B; RAW264.7 cells are resuspended after centrifugation, homogenized and centrifuged again to collect the supernatant, and the supernatant centrifugal precipitation is the prepared macrophage membrane C; the configured B solution and C are mixed, and a bionic nanomaterial D wrapped in a macrophage membrane coating is prepared by a direct extrusion method. The inhalable bionic nanomaterial prepared by the present invention can cross the complex lung barrier to target the inflammatory site to respond to the release of drugs, and can remove reactive oxygen to relieve lung inflammation, which is of great significance for the treatment of lung infection and has promotion and application value.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

This invention relates to the field of traditional Chinese medicine technology, and more particularly to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of lung injury. The traditional Chinese medicine composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that this traditional Chinese medicine composition can significantly reduce the level of the inflammatory factor TNF-α, decrease the lung index, and alleviate pathological damage to lung tissue, and can be used for the prevention and treatment of lung injury.

This application discloses the use of itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of biomedical technology. The itaconic acid derivatives proposed in this application are dimethyl itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a dose-dependent therapeutic effect in model mice, with an optimal dose of 1200 mg / kg improving survival rate and reducing kidney damage; 4-octyl itaconic acid can enhance the anti-Candida albicans ability of macrophages and regulate the expression of inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in toxicity, have good biocompatibility, and use a universal experimental system, providing a new approach for the clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.

The invention relates to the technical field of medicines, in particular to application of aleppo avens in preparation of medicines for treating pulmonary fibrosis diseases. The aleppo avens and the aleppo avens extract with the pulmonary fibrosis disease effect are specifically provided, the aleppo avens aqueous extract (LBZ) can remarkably improve the survival quality of mice, reduce the lung coefficient and the HYP level of pulmonary fibrosis disease individuals and remarkably relieve pathological injuries of the pulmonary fibrosis individuals; the TGF-beta 1 and alpha-SMA proteins are reduced to different degrees; the levels of MDA, serum IL-6 and TNF-alpha are reduced, and the SOD level is improved; the levels of IL-6 and TNF-alpha are reduced to different degrees, the lung tissue of an individual with pulmonary fibrosis is remarkably reduced, and the in-vivo inflammatory response is relieved; the SOD level in the lung tissue is increased, the MDA level is reduced, the oxidative stress injury of the lung tissue is relieved, and then the symptoms of an individual suffering from the pulmonary fibrosis disease are improved. An effective medicine and a new treatment thought are provided for treating the IPF.

The invention discloses bifidobacterium longum CCFM1509 with autophagy promoting and colon aging resisting functions and application of the bifidobacterium longum CCFM1509, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1509 provided by the invention can relieve colon tissue pathological damage caused by senescence, reduce the level of proinflammatory cytokines in colon tissues, reduce the oxidative stress level in the colon tissues, reduce the level of senescence-related senescence markers in the colon tissues and adjust the autophagy level in the colon tissues. Therefore, the bifidobacterium longum CCFM1509 disclosed by the invention can be widely applied to the field of medicines and is used for preparing pharmaceutical preparations for preventing or treating colon aging and related diseases; meanwhile, the bacillus subtilis can also be used for developing various functional fermented foods, health foods and formula foods for special medical purposes, provides a new microbial solution for promoting intestinal health and delaying colon senescence, and has important development value and wide market prospects.

The invention discloses an application of a Yinxiaonaotong soft capsule in preparation of a medicine for preventing and treating acute lung injury, and experimental research shows that the Yinxiaonaotong soft capsule can significantly improve lung histopathologic injury of an acute lung injury mouse model activated and induced by a complement bypass and relieve inflammatory cell infiltration. The mechanism of action is as follows: the Yindanaotong can effectively inhibit the expression of key inflammatory mediators (TNF-alpha, IL-6) and adhesion molecules (ICAM-1, P-selectin) in lung tissues and serum. Meanwhile, the medicine can down-regulate the mRNA transcriptional level of NF-kappa B p65, JNK, p38 MAPK and STAT3 signal channel related genes in lung tissues and inhibit phosphorylation activation of corresponding proteins. The results comprehensively show that the Yindan Xinnaotong compound intervenes in an inflammation signal channel through multiple targets, and plays roles in resisting inflammation and protecting lung tissues, so that the Yindan Xinnaotong compound can be used for preparing medicines for preventing and / or treating acute lung injury.

The invention discloses application of lactobacillus delbrueckii JNL0010 in preparation of uric acid lowering drugs, and belongs to the technical field of microorganisms. The lactobacillus delbrueckii JNL0010 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 31042. Animal experiment results show that the lactobacillus delbrueckii JNL0010 can significantly reduce the blood uric acid level of a hyperuricemia model mouse and relieve the kidney inflammation level, and shows huge application value. The lactobacillus delbrueckii JNL0010 not only can degrade purine and nucleoside and reduce serum uric acid, but also has a certain protection effect on kidneys, and compared with drugs, the lactobacillus delbrueckii JNL0010 is higher in safety, small in side effect and wide in market prospect.

The invention discloses an application of a small molecule drug ATWLPPR Peptide TFA in resisting mycobacterium bovis infection, and belongs to the field of biological medicine, the small molecule drug ATWLPPR Peptide TFA is an agonist of a target host factor NRP1, and then the inhibition effect of the ATWLPPR Peptide TFA on mycobacterium bovis in vitro and in vivo is researched. An in-vitro bacterial loading titration result shows that the ATWLPPR Peptide TFA treatment can present dose-dependent inhibition of the mycobacterium bovis to adhere to A549 cells. Mouse experiment results show that ATWLPPR Peptide TFA treatment can inhibit mice from being infected with mycobacterium bovis, pathological injuries of mouse lung tissues are effectively relieved, and a brand new direction is provided for prevention and control of mycobacterium bovis.

The invention belongs to the field of biological medicine, provides application of an interference NLK gene target spot in preparation of a medicine for improving macrophage inflammatory activation, and discloses application of an NLK gene in macrophage differential polarization regulation of sepsis inflammatory response period. A mouse in-vivo experiment proves that in a sepsis state, NLK gene up-regulation mediates inflammatory activation of macrophages; interference on NLK expression can promote the inflammatory activation of macrophages to be converted into an anti-inflammatory activation state, and the inflammatory response and the survival rate of sepsis mice are effectively improved. Research results show that the NLK gene is expected to become a drug target for treating sepsis.

The invention discloses an African swine fever virus replication-deficient strain as well as a preparation method and application thereof, and belongs to the technical field of African swine fever viruses. The African swine fever virus replication-deficient strain is obtained by fusing escherichia coli dihydrofolate reductase on p54 protein of African swine fever virus, the nucleotide sequence of the escherichia coli dihydrofolate reductase is as shown in SEQ ID No.1, and the African swine fever virus is an ASFV CN / GS 2018 strain. The African swine fever virus replication-deficient strain is obtained by fusing an unstable structural domain onto a p54 protein, degradation of the p54 protein is regulated and controlled by using a micromolecular ligand trimethoprim, so that replication and proliferation of the virus are regulated and controlled, and the strain has important application values in the aspects of reducing virus toxicity, enhancing vaccine safety, promoting vaccine research and development and the like.

This invention relates to mitochondrial-enriched extracellular vesicles, their preparation methods, and applications, which can effectively solve the drug problem in spontaneous intracerebral hemorrhage. The technical solution involves using platelets as raw material, and obtaining platelet-derived extracellular vesicles carrying active mitochondria through activation induction, differential centrifugation and fractionation, membrane filtration and elution enrichment. This achieves efficient and stable loading of functional mitochondria, and the resulting PEV Mito has a complete structure and uniform particle size, which can effectively maintain mitochondrial membrane potential and biological activity. It can achieve efficient delivery and intracellular internalization to damaged neurons and restore mitochondrial function. The PEV Mito prepared by this invention has high delivery efficiency and excellent biocompatibility, and can be used to prepare drugs for the treatment of intracerebral hemorrhage and secondary neurological injury, with good prospects for clinical translation.

The application provides application of tanshinone or a derivative thereof in preparation of a monkeypox virus resisting drug. In a cell model infected by the monkeypox virus, production of infectious virus particles can be significantly reduced. In a mouse infection model, Tanshinone VII can effectively reduce pathological damage of lung tissues and improve survival rate of animals. The above evidence indicates that Tanshinone VII has potential efficacy in resisting the monkeypox virus. It is inferred that tanshinone or the derivative thereof can play a double role in resisting the monkeypox virus and host protection.

The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a traditional Chinese medicine composition for treating hepatic fibrosis and a preparation method thereof. According to the invention, astragalus membranaceus, vinegar-processed curcuma zedoary, salvia miltiorrhiza, moutan bark, radix paeoniae rubra, angelica sinensis, curcuma aromatica, fructus amomi, bran-fried atractylodes macrocephala koidz, poria cocos, fingered citron, vinegar-processed bupleurum chinense and honey-fried licorice root are adopted as raw materials and are subjected to proper weight proportioning; wherein the astragalus membranaceus is a monarch drug, and the vinegar curcuma zedoary, the salvia miltiorrhiza, the moutan bark, the red paeony root, the angelica sinensis, the radix curcumae, the fructus amomi and the bran-fried rhizoma atractylodis macrocephalae are The vinegar bupleurum chinense, fingered citron and poria cocos are used as adjuvant drugs, and the liquorice is used as conductant drug; all the medicines are combined to achieve the effects of replenishing qi to invigorate the spleen, soothing the liver, regulating qi and promoting blood circulation to remove blood stasis. Under the synergistic effect of all the medicine components, the traditional Chinese medicine composition has a good curative effect on liver fibrosis, especially liver fibrosis common clinically with liver depression, spleen deficiency and blood stasis syndromes, and is small in toxic and side effect and worthy of clinical application and popularization.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum TY-M21 and application of the lactobacillus plantarum TY-M21, and the preservation number of the lactobacillus plantarum TY-M21 is CGMCC (China General Microbiological Culture Collection Center) No. 29230. The lactobacillus plantarum TY-M21 has relatively high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus plantarum TY-M21 can be used for remarkably relieving diabetes characteristics of mice with type II diabetes, remarkably reducing fasting blood-glucose level, remarkably improving insulin resistance and serum insulin level, remarkably reducing serum Glu level and serum TG level, and remarkably improving insulin resistance and serum insulin level. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus plantarum TY-M21 has the advantages that the lactobacillus plantarum TY-M21 can be used for preparing the lactobacillus plantarum TY-M21, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus plantarum TY-M21 has

This invention discloses the application of the small molecule compound Z2114502286 in the preparation of drugs for the prevention and treatment of liver-related diseases. This invention reveals for the first time that Z2114502286 is a THBS2-specific small molecule inhibitor and verifies its feasibility in preventing and treating liver fibrosis by targeting and inhibiting the THBS2 protein. Through virtual screening and molecular docking, this compound can directly bind to the THBS2 protein. In vitro and in vivo studies show that this compound inhibits THBS2-mediated HSC activation in a concentration- and time-dependent manner, inhibits ECM deposition in a mouse model of liver fibrosis, downregulates the expression of fibrosis-related genes, and alleviates liver inflammation and macrophage infiltration. Simultaneously, the targeted efficacy was verified in a transgenic mouse model specifically expressing human THBS2, demonstrating significant clinical translational value. Furthermore, it exhibits bioavailability and safety at effective dosages, showing broad clinical application prospects.

This invention provides the application of a uterine-derived Sphingomonas DS-28 strain and its metabolites in the treatment of endometritis, relating to the field of microbial technology. The Sphingomonas DS-28 strain provided by this invention possesses uterine colonization ability, good niche adaptability, and significant efficacy in treating Escherichia coli-induced endometritis. Animal experiments show that the preparation of this strain can effectively alleviate uterine redness and swelling, reduce pathological damage, and significantly reduce [the condition / progression]. TNF-alpha , IL-6 , IL-8 It inhibits gene expression and suppresses the NF-κB signaling pathway, exhibiting superior anti-inflammatory and tissue repair effects compared to other Sphingomonas strains C3-25.1, C3-41.1, and C3-42.1. Furthermore, the metabiotic preparation of this strain can also alleviate Escherichia coli-induced endometritis in mice, improve uterine redness and swelling, and reduce pathological damage.

The invention belongs to the technical field of medicines, and particularly relates to application of a traditional Chinese medicine compound composition in preparation of medicines for resisting acute and chronic renal injury and renal fibrosis. The traditional Chinese medicine compound composition has remarkable effects of resisting acute kidney injury and chronic kidney injury and improving the degree of renal fibrosis caused by the kidney injury, and can be used for improving and treating acute and chronic kidney injury and renal fibrosis diseases caused by the kidney injury. According to the traditional Chinese medicine compound composition, the acute and chronic renal injury is treated by reducing the oxidative stress level, regulating an inflammation signal channel and inhibiting kidney inflammation so as to regulate and control the immune microenvironment of the kidney, and the renal fibrosis caused by the renal injury is improved. The invention provides a new medicine with obvious curative effect and small adverse reaction for patients with acute and chronic renal injury and renal fibrosis caused by renal injury, so as to relieve the pain of the patients.

The application provides an application of exemestane or a derivative thereof in preparation of a medicine for protecting against radiation-induced intestinal injury, and further provides a medicine composition for protecting against radiation-induced intestinal injury, which is composed of exemestane or a derivative thereof and pharmaceutically acceptable adjuvants. The application first screens and locks the exemestane from a high-throughput screening of 3067 compounds approved by FDA. Through a mouse model of radiation-induced intestinal injury, it is verified that the survival rate of mice can be significantly improved by intragastrically treating the mice with 6.25 mg / kg of exemestane 2 hours before whole body 8 Gy irradiation. HE histology shows that the intestinal crypt-villus structure integrity of the mice in the exemestane administration group is recovered, the bone marrow cavity emptiness degree is reduced, and the spleen injury is reduced. The above results prove that the exemestane can protect the intestine, hematopoietic and immune organs at the whole animal level, and is a rare small molecule compound for protecting multiple organs. The application provides a new basis for exemestane or a derivative thereof for protecting against radiation-induced intestinal injury.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of hybrid peptide B5PL and its application in preparation of anti-infection drugs.The amino acid sequence of the hybrid peptide B5PL is shown as SEQ ID NO.1, and research proves that the hybrid peptide B5PL can destroy bacterial cell membranes, regulate immune homeostasis, and thus play a role in preventing and treating drug-resistant Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, Streptococcus suis and Actinobacillus pleuropneumoniae infections.In a mouse peritoneal infection MRSA model, B5PL can significantly reduce lung pathological damage caused by infection, specifically manifested as improved alveolar structure integrity, reduced inflammatory cell infiltration, and significantly improved mouse survival rate, showing good anti-infection treatment potential.The hybrid peptide B5PL provided by the application is expected to become an antibiotic replacement drug, and has good application prospect.

The invention discloses application of berbamine in preparation of a ferroptosis inhibitor and / or a drug for preventing and treating drug-induced liver injury, the ferroptosis inhibitor is a hepatocyte ferroptosis inhibitor, and the drug is a drug for drug-induced liver injury induced by acetaminophen. The invention also provides application of berbamine in preparation of a liver enzyme inhibitor, an APAP-induced liver tissue oxidative stress inhibitor, a ferroptosis signaling pathway protein expression promoter and a liver tissue ferroptosis marker PTGS2 expression inhibitor. The application has the advantages that the fact that berbamine can inhibit hepatocyte ferroptosis by regulating an NRF2 / GCLC / GPX4 antioxidant axis and an FSP1 pathway is revealed for the first time, so that a new treatment strategy is provided for ferroptosis related diseases and drug-induced liver injury.